Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Acronyms

3. Research Methodology

4. Executive Summary: Global Biosimilars Market

5. Market Overview
5.1. Definition
5.2. Market Indicators
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunities

6. Market Outlook
6.1. Global Biosimilars Market Analysis and Forecast, 2017–2031
6.2. Global Biosimilars Market Outlook
6.3. Entry Barriers to Biosimilars Market
6.4. Factors Driving the Adoption of Biosimilars
6.5. Pipeline Analysis
6.6. Regulatory Scenario Assessment
6.7. Key Industry Developments

7. Global Biosimilars Market Analysis and Forecast, by Product
7.1. Introduction
7.2. Biosimilars Market Value Forecast, by Product, 2017–2031
7.2.1. Recombinant Glycosylated Proteins
7.2.1.1. Monoclonal Antibodies
7.2.1.2. Erythropoietin
7.2.1.3. Others
7.2.2. Recombinant Non-glycosylated Proteins
7.2.2.1. Insulin
7.2.2.2. Granulocyte Colony Stimulating Factor
7.2.2.3. Recombinant Human Growth Factor
7.2.2.4. Interferons
7.2.3. Recombinant Peptides
7.3. Market Attractiveness Analysis, by Product

8. Global Biosimilars Market Analysis and Forecast, by Indication
8.1. Introduction
8.2. Biosimilars Market Value Forecast, by Indication, 2017–2031
8.2.1. Chronic Diseases
8.2.2. Oncology
8.2.3. Autoimmune Diseases
8.2.4. Infectious Diseases
8.2.5. Blood Disorders
8.2.6. Growth Hormone Deficiency
8.2.7. Others
8.3. Market Attractiveness Analysis, by Material

9. Global Biosimilars Market Analysis and Forecast, by Region
9.1. Regional Outlook
9.2. Global Scenario
9.3. Introduction
9.4. Biosimilars Market Value Forecast, by Region
9.4.1. North America
9.4.2. Europe
9.4.3. Asia Pacific
9.4.4. Latin America
9.4.5. Middle East & Africa
9.5. Market Attractiveness Analysis, by Region

10. North America Biosimilars Market Analysis and Forecast
10.1. Key Findings
10.2. North America Biosimilars Market Value Forecast, by Product, 2017–2031
10.2.1. Recombinant Glycosylated Proteins
10.2.1.1. Monoclonal Antibodies
10.2.1.2. Erythropoietin
10.2.1.3. Others
10.2.2. Recombinant Non-glycosylated Proteins
10.2.2.1. Insulin
10.2.2.2. Granulocyte Colony Stimulating Factor
10.2.2.3. Recombinant Human Growth Factor
10.2.2.4. Interferons
10.2.3. Recombinant Peptides
10.3. North America Biosimilars Market Value Forecast, by Indication, 2017–2031
10.3.1. Chronic Diseases
10.3.2. Oncology
10.3.3. Autoimmune Diseases
10.3.4. Infectious Diseases
10.3.5. Blood Disorders
10.3.6. Growth Hormone Deficiency
10.3.7. Others
10.4. North America Biosimilars Market Value Forecast, by Country, 2017–2031
10.4.1. U.S.
10.4.2. Canada
10.5. North America Biosimilars Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Indication
10.5.3. By Country

11. Europe Biosimilars Market Analysis and Forecast
11.1. Key Findings
11.2. Europe Biosimilars Market Value Forecast, by Product, 2017–2031
11.2.1. Recombinant Glycosylated Proteins
11.2.1.1. Monoclonal Antibodies
11.2.1.2. Erythropoietin
11.2.1.3. Others
11.2.2. Recombinant Non-glycosylated Proteins
11.2.2.1. Insulin
11.2.2.2. Granulocyte Colony Stimulating Factor
11.2.2.3. Recombinant Human Growth Factor
11.2.2.4. Interferons
11.2.3. Recombinant Peptides
11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017–2031
11.3.1. Chronic Diseases
11.3.2. Oncology
11.3.3. Autoimmune Diseases
11.3.4. Infectious Diseases
11.3.5. Blood Disorders
11.3.6. Growth Hormone Deficiency
11.3.7. Others
11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. U.K.
11.4.2. Germany
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Rest of Europe
11.5. Europe Biosimilars Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Indication
11.5.3. By Country/Sub-region

12. Asia Pacific Biosimilars Market Analysis and Forecast
12.1. Key Findings
12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017–2031
12.2.1. Recombinant Glycosylated Proteins
12.2.1.1. Monoclonal Antibodies
12.2.1.2. Erythropoietin
12.2.1.3. Others
12.2.2. Recombinant Non-glycosylated Proteins
12.2.2.1. Insulin
12.2.2.2. Granulocyte Colony Stimulating Factor
12.2.2.3. Recombinant Human Growth Factor
12.2.2.4. Interferons
12.2.3. Recombinant Peptides
12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017–2031
12.3.1. Chronic Diseases
12.3.2. Oncology
12.3.3. Autoimmune Diseases
12.3.4. Infectious Diseases
12.3.5. Blood Disorders
12.3.6. Growth Hormone Deficiency
12.3.7. Others
12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. China
12.4.2. India
12.4.3. Japan
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Biosimilars Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Indication
12.5.3. By Country/Sub-region

13. Latin America Biosimilars Market Analysis and Forecast
13.1. Key Findings
13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017–2031
13.2.1. Recombinant Glycosylated Proteins
13.2.1.1. Monoclonal Antibodies
13.2.1.2. Erythropoietin
13.2.1.3. Others
13.2.2. Recombinant Non-glycosylated Proteins
13.2.2.1. Insulin
13.2.2.2. Granulocyte Colony Stimulating Factor
13.2.2.3. Recombinant Human Growth Factor
13.2.2.4. Interferons
13.2.3. Recombinant Peptides
13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017–2031
13.3.1. Chronic Diseases
13.3.2. Oncology
13.3.3. Autoimmune Diseases
13.3.4. Infectious Diseases
13.3.5. Blood Disorders
13.3.6. Growth Hormone Deficiency
13.3.7. Others
13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Biosimilars Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Indication
13.5.3. By Country/Sub-region
14. Middle East & Africa Biosimilars Market Analysis and Forecast
14.1. Key Findings
14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017–2031
14.2.1. Recombinant Glycosylated Proteins
14.2.1.1. Monoclonal Antibodies
14.2.1.2. Erythropoietin
14.2.1.3. Others
14.2.2. Recombinant Non-glycosylated Proteins
14.2.2.1. Insulin
14.2.2.2. Granulocyte Colony Stimulating Factor
14.2.2.3. Recombinant Human Growth Factor
14.2.2.4. Interferons
14.2.3. Recombinant Peptides
14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017–2031
14.3.1. Chronic Diseases
14.3.2. Oncology
14.3.3. Autoimmune Diseases
14.3.4. Infectious Diseases
14.3.5. Blood Disorders
14.3.6. Growth Hormone Deficiency
14.3.7. Others
14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East & Africa
14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis
14.5.1. By Product
14.5.2. By Indication
14.5.3. By Country/Sub-region

15. Competition Landscape
15.1. Competition Matrix
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Intas Pharmaceuticals Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Biocon
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Dr. Reddy’s Laboratories Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Teva Pharmaceutical Industries Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Sandoz International GmbH (A Novartis Division)
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Celltrion, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Amgen, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. STADA Arzneimittel AG
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
15.3.10. Apotex Inc. (Apobiologix)
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Strategic Overview
15.3.10.5. SWOT Analys



List of Figures

List of Figures

Figure 01: Global Biosimilars Market Snapshot

Figure 02: Global Biosimilars Market Value (US$ Bn) by Region, 2021 and 2031

Figure 03: Global Biosimilars Market Value (US$ Bn) Forecast, 2021–2031

Figure 04: Global Biosimilars Market Value Share (%), by Product, 2021

Figure 05: Global Biosimilars Market Value Share (%), by Indication, 2021

Figure 06: Global Biosimilars Market Value Share (%), by Region, 2021

Figure 07: Entry Barriers to Biosimilars Market

Figure 08: Factors Driving the Adoption of Biosimilars

Figure 09: Biosimilar Approval Process - US

Figure 10: Data Requirements for Biosimilar Approval in Europe

Figure 11: Regulations for Biosimilar Approval in Japan

Figure 12: Regulations for Biosimilar Approval in India

Figure 13: Regulations for Biosimilar Approval in Brazil

Figure 14: Regulations for Biosimilar Approval in Saudi Arabia

Figure 15: Biosimilars Market - Key Product Launches

Figure 16: Global Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 17: Global Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 18: Global Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 19: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Figure 20: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Figure 21: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Peptides, 2017–2031

Figure 22: Global Biosimilars Market Value (US$ Bn) Forecast, by Monoclonal Antibodies, 2017–2031

Figure 23: Global Biosimilars Market Value (US$ Bn) Forecast, by Erythropoietin, 2017–2031

Figure 24: Global Biosimilars Market Value (US$ Bn) Forecast, by Others, 2017–2031

Figure 25: Global Biosimilars Market Value (US$ Bn) Forecast, by Insulin, 2017–2031

Figure 26: Global Biosimilars Market Value (US$ Bn) Forecast, by Granulocyte Colony Stimulating Factor, 2017–2031

Figure 27: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Human Growth Factor, 2017–2031

Figure 28: Global Biosimilars Market Value (US$ Bn) Forecast, by Interferons, 2017–2031

Figure 29: Global Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 30: Global Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 31: Global Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 32: Global Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 33: Global Biosimilars Market Value (US$ Bn) Forecast, by Chronic Diseases, 2017–2031

Figure 34: Global Biosimilars Market Value (US$ Bn) Forecast, by Oncology, 2017–2031

Figure 35: Global Biosimilars Market Value (US$ Bn) Forecast, by Autoimmune Diseases, 2017–2031

Figure 36: Global Biosimilars Market Value (US$ Bn) Forecast, by Infectious Diseases, 2017–2031

Figure 37: Global Biosimilars Market Value (US$ Bn) Forecast, by Blood Disorders, 2017–2031

Figure 38: Global Biosimilars Market Value (US$ Bn) Forecast, by Growth Hormone Deficiency, 2017–2031

Figure 39: Global Biosimilars Market Value (US$ Bn) Forecast, by Others, 2017–2031

Figure 40: Global Biosimilars Market Attractiveness Analysis, by Indication, 2021-2031

Figure 41: Global Biosimilars Market: Regional Outlook

Figure 42: Global Biosimilars Market Value Share Analysis, by Region, 2021 and 2031

Figure 43: Global Biosimilars Market Attractiveness Analysis, by Region, 2021-2031

Figure 44: North America Biosimilars Market Value (US$ Bn) Forecast, 2017–2031

Figure 45: North America Biosimilars Market Value Share Analysis, by Country, 2021 and 2031

Figure 46: North America Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 47: North America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 48: North America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 49: North America Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 50: North America Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 51: North America Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 52: North America Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 53: North America Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 54: North America Biosimilars Market Attractiveness Analysis, by Country, 2021 and 2031

Figure 55: Europe Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 56: Europe Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 57: Europe Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 58: Europe Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 59: Europe Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 60: Europe Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 61: Europe Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 62: Europe Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 63: Europe Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 64: Europe Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 65: Europe Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

Figure 66: Asia Pacific Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 67: Asia Pacific Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 68: Asia Pacific Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 69: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 70: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 71: Asia Pacific Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 72: Asia Pacific Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 73: Asia Pacific Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 74: Asia Pacific Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 75: Asia Pacific Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 76: Asia Pacific Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

Figure 77: Latin America Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 78: Latin America Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 79: Latin America Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 80: Latin America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 81: Latin America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 82: Latin America Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 83: Latin America Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 84: Latin America Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 85: Latin America Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 86: Latin America Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 87: Latin America Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

Figure 88: Middle East & Africa Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 89: Middle East & Africa Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 90: Middle East & Africa Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

Figure 91: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 92: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 93: Middle East & Africa Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

Figure 94: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

Figure 95: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

Figure 96: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

Figure 97: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

Figure 98: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

Figure 99: Global Biosimilars Market Share Analysis, by Company, 2018

List of Tables

List of Tables

Table 01: Pipeline Analysis - Biosimilars

Table 02: Global Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

Table 03: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 04: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 05: Global Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 06: Global Biosimilars Market Value (US$ Bn) Forecast, by Region, 2017–2031

Table 07: North America Biosimilars Market Value (US$ Bn) Forecast, by Country, 2017–2031

Table 08: North America Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017–2031

Table 09: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 10: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 11: North America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 12: Europe Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Europe Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017–2031

Table 14: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 15: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 16: Europe Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 17: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

Table 19: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 20: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 21: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 22: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 23: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

Table 24: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 25: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 26: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

Table 27: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 28: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

Table 29: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

Table 30: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

Table 31: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031